|Writing Group Member||Employment||Research Grant||Other Research Support||Speakers Bureau/Honoraria||Expert Witness||Ownership Interest||Consultant/Advisory Board||Other|
|Michael J. Ackerman||Mayo Clinic||NIH (R01 grants)†||None||None||None||None||Boston Scientific∗; Gilead Sciences∗; Medtronic∗; St. Jude Medical∗||Transgenomic†|
|Richard J. Kovacs||Indiana University||None||None||None||None||None||None||None|
|Barry J. Maron||Minneapolis Heart Institute Foundation||None||None||None||None||None||None||None|
|Douglas P. Zipes||Indiana University||None||None||None||None||None||None||None|
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.